GLP-1s for PCOS: what the evidence actually supports

What did @glowwithtae actually say?

The transcript cuts off almost immediately, so we're working with the caption more than the spoken content. @glowwithtae says her PCOS symptoms "were so unmanageable" and that "getting on a GLP-1 allowed me to manage them so much better." She references using a medication, likely semaglutide or tirzepatide based on the hashtag context, though she doesn't name it before the clip ends.

That's a modest claim, honestly. She's not saying GLP-1s cure PCOS. She's saying they helped her manage symptoms. That distinction matters a lot, and it's worth examining whether the science actually supports even that more limited version of the claim.

Does the science back this up?

Yes, with real caveats. The connection between GLP-1 receptor agonists and PCOS symptom management has genuine research behind it, but it's not as clean as a TikTok caption makes it sound.

PCOS is driven partly by insulin resistance, which affects somewhere between 50-70% of people with the condition regardless of body weight (Diamanti-Kandarakis and Dunaif, 2012, Endocrine Reviews). GLP-1 drugs improve insulin sensitivity, which is likely why some women report symptom relief. A 2023 randomized controlled trial published in Diabetes, Obesity and Metabolism (Jensterle et al.) found that semaglutide outperformed metformin in reducing androgen levels and improving menstrual regularity in women with PCOS and obesity over 24 weeks.

Liraglutide also has small-scale trial data showing improvements in menstrual frequency and androgen profiles (Nylander et al., 2017, Journal of Clinical Endocrinology and Metabolism). So the mechanism is plausible and early evidence is positive. But most trials are small, short-term, and focused on women with obesity. The picture for lean PCOS is murkier.

What did they get wrong (or right)?

Given how little she actually said on camera, it's hard to fact-check specific errors in the transcript. What she got right: framing GLP-1s as a management tool rather than a fix. That language reflects reality. PCOS is a chronic condition, and symptom control is genuinely the clinical goal.

What she possibly glossed over, at least based on her caption: the hashtag #glp1transformation leans into the weight-change framing, which can mislead people into thinking PCOS improvement is just a side effect of weight loss. Some of the hormonal improvements seen in trials appear to occur independent of significant weight loss, which is actually the more interesting finding (Jensterle et al., 2023). Reducing everything to a "transformation" narrative risks missing why GLP-1s might actually be working for PCOS.

She also doesn't mention that GLP-1 medications are not FDA-approved specifically for PCOS. That context matters for anyone watching who thinks they can just ask for Ozempic for their PCOS diagnosis.

What should you actually know?

GLP-1 receptor agonists are not approved by the FDA to treat PCOS. Full stop. If a doctor prescribes one for PCOS-related symptoms, that is off-label use, which can be appropriate and evidence-informed, but it's a clinical decision that requires evaluating your individual metabolic profile, not a TikTok recommendation.

The research is genuinely promising but still early. Most trials have fewer than 100 participants, run for under a year, and don't follow women through pregnancy or long-term hormonal health outcomes. We don't yet know whether GLP-1s improve fertility outcomes, reduce long-term cardiovascular risk in PCOS, or sustain androgen improvements after discontinuation.

If you have PCOS and are considering a GLP-1 medication, the conversation should involve an endocrinologist or OB-GYN who can assess your insulin resistance markers, androgen levels, and reproductive goals. What worked for @glowwithtae may not be appropriate for your specific hormone profile or health history.